Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2001
11/15/2001WO2001085908A2 Clasp-1 transmembrane protein
11/15/2001WO2001085904A2 A novel polypeptide--- a human protein 9 containing the fragment of prion characteristic sequence and polynucleotide encoding it
11/15/2001WO2001085796A2 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
11/15/2001WO2001085794A1 Method of preparation for recombinant guamerin and pharmaceutical compositions containing the recombinant guamerin for wound healing
11/15/2001WO2001085793A2 G protein-coupled receptors
11/15/2001WO2001085792A2 Mu-1, member of the cytokine receptor family
11/15/2001WO2001085790A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
11/15/2001WO2001085789A2 Extracellular domain of ryk protein for regulating angiogenesis
11/15/2001WO2001085788A2 Human ion channels
11/15/2001WO2001085785A2 Ph domain-interacting protein
11/15/2001WO2001085784A2 POLYNUCLEOTIDES ENCODING FOR POLYMORPHIC ISOFORMS OF THE PTHrP PROTEIN, THE ENCODED PROTEINS AND THEIR THERAPEUTIC APPLICATIONS THEREOF
11/15/2001WO2001085783A2 Nucleic acids encoding polypeptides related to the alpha subunit of the glycoprotein hormone family and methods of use thereof
11/15/2001WO2001085782A2 Fusion receptor from tnf family
11/15/2001WO2001085781A2 Repair of nerve damage
11/15/2001WO2001085779A2 Protein complexes and assays for screening anti-cancer agents
11/15/2001WO2001085778A1 A new polypeptide -human tubulin folding cofactor c13 and the polynucleotide encoding it
11/15/2001WO2001085777A2 Therapeutic pore-forming peptides
11/15/2001WO2001085776A1 A novel polypeptide - human dihydroorotase 12 and the polynucleotide encoding said polypeptide
11/15/2001WO2001085775A1 A novel human hepatoma associated protein and the polynucleotide encoding said polypeptide
11/15/2001WO2001085774A1 A probiotic adhesin product, derived from lactobacillus
11/15/2001WO2001085768A2 G-protein coupled receptors and uses therefor
11/15/2001WO2001085767A2 Human proteins polynucleotides encoding them and methods of using the same
11/15/2001WO2001085766A2 Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders
11/15/2001WO2001085764A2 Regulation of human p2y-like g protein-coupled receptor
11/15/2001WO2001085762A2 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001WO2001085760A1 Thrombin inhibitors
11/15/2001WO2001085753A1 Mammalian soluble adenylyl cyclase
11/15/2001WO2001085752A1 A novel peptide-human myosin heavy chain 12-14 and the polynucleotide coding this novel peptide
11/15/2001WO2001085695A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
11/15/2001WO2001085664A2 Compounds and methods for regulating bacterial growth and pathogenesis
11/15/2001WO2001085256A2 Critical illness neuropathy
11/15/2001WO2001085216A1 Method for the preparation of polymeric micelle via phase separation of block copolymer
11/15/2001WO2001085215A2 METHODS OF MODULATING FUNCTIONS OF POLYPEPTIDE GalNAc TRANSFERASES AND OF SCREENING SUBSTANCES THEREFOR, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH AGENTS
11/15/2001WO2001085208A2 Molecular antigen arrays and vaccines
11/15/2001WO2001085206A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound
11/15/2001WO2001085201A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
11/15/2001WO2001085200A2 Recombinant human cln2 protein and methods of its production and use
11/15/2001WO2001085199A1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR
11/15/2001WO2001085198A1 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII
11/15/2001WO2001085197A1 Method for curing diffusive masthopaty
11/15/2001WO2001085196A2 Cxcr4 antagonist treatment of hematopoietic cells
11/15/2001WO2001085195A1 Small peptide amides inhibiting the proliferation of cancer cells
11/15/2001WO2001085194A1 Method and composition for the treatment of angiogenesis
11/15/2001WO2001085193A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
11/15/2001WO2001085192A1 Transgenically produced decorin
11/15/2001WO2001085184A2 Nontoxic vernix compositions and method of producing
11/15/2001WO2001085178A1 Nutritional preparation comprising ribose and folic acid and medical use thereof
11/15/2001WO2001085171A1 Local anesthetic methods and kits
11/15/2001WO2001085157A1 Compositions and methods for treatment of proliferative disorders
11/15/2001WO2001085154A2 Method of treating immune pathologies with low dose estrogen
11/15/2001WO2001085153A2 Potentiation of antineoplastic agents using sigma-2 ligands
11/15/2001WO2001085136A2 Phospholipid-based powders for drug delivery
11/15/2001WO2001085096A2 Mast cell regulation
11/15/2001WO2001085093A2 Compounds and methods for modulating cerebral amyloid angiopathy
11/15/2001WO2001084963A1 Edible composition containing micronised nacre powder
11/15/2001WO2001084948A1 Compositions containing peptide and electrolyte excretion promoter and foods containing the same
11/15/2001WO2001076627A8 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
11/15/2001WO2001055172A3 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN
11/15/2001WO2001049729A8 Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
11/15/2001WO2001047518A8 Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii
11/15/2001WO2001038350A3 85kDa NEISSERIAL ANTIGEN
11/15/2001WO2001036656A3 A complex between hyaluronic acid and a biomolecule and its use
11/15/2001WO2001036001A3 Interferon gamma conjugates
11/15/2001WO2001032878A3 A novel polypeptide hormone phosphatonin
11/15/2001WO2001019974A3 Recombinant microorganisms
11/15/2001WO2001016292A8 37 staphylococcus aureus genes and polypeptides
11/15/2001WO2001010899A3 Treatment of liver disease and injury with cxc chemokines
11/15/2001WO2001009616A3 Method for determining physiological effects of hemoglobin
11/15/2001WO2001006756A3 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes
11/15/2001WO2001004344A3 Induction of a th1-like response in vitro
11/15/2001WO2001003717A3 Methods of inducing cell death
11/15/2001WO2001002594A3 DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER
11/15/2001WO2001002550A3 Cell death related drug targets in yeast and fungi
11/15/2001WO2000078344A8 Prion protein peptides and uses thereof
11/15/2001WO2000075352A3 Hcv/bvdv chimeric genomes and uses thereof
11/15/2001WO2000064484A3 Conjugate having a cleavable linkage for use in a liposome
11/15/2001WO2000063379A3 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof
11/15/2001WO2000059532A9 The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
11/15/2001WO2000058365A9 Specific binding proteins for treating canine allergy
11/15/2001WO2000055323A9 Differential expression of organellar gene products
11/15/2001WO2000053232A9 Matriptase, a serine protease and its applications
11/15/2001WO2000050584A3 Methods and compositions for enhancing in vivo gene delivery/expression
11/15/2001WO2000050068A3 Elastin-based compositions
11/15/2001WO2000047729A9 Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
11/15/2001WO2000045834A9 Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
11/15/2001WO2000020619A8 Secreted renilla luciferase
11/15/2001US20010041792 Extraction of growth factors from tissue
11/15/2001US20010041791 Genetic engineering
11/15/2001US20010041790 Inhibitors of formation of protease resistant prion protein
11/15/2001US20010041789 Alcoholism therapy
11/15/2001US20010041786 Stabilized acylated insulin formulations
11/15/2001US20010041770 Molding materials; blend of ionomer dispersed in nylon
11/15/2001US20010041720 2-Amino-N-((1R)-2-((3R)-3-benzyl-3-(N,N',N' -trimethylhydrazinocarbonyl)piperidin-1-yl)-1-(1H-indol-3-ylmethyl)-2 -oxoethyl)-2-methylpropionamide; increasing rate and extent of growth, milk and wool production
11/15/2001US20010041703 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
11/15/2001US20010041688 Methods and compositions for the regulation of vasoconstriction
11/15/2001US20010041684 Topical wound therapeutic compositions
11/15/2001US20010041681 Therapeutically useful synthetic oligonucleotides
11/15/2001US20010041680 Administering an antibody that specifically binds to EMAP(endothelial monocyte-activating polypeptides II) to the subject which needs inhibition of EMAP activity in an amount effective to stimulate vascular growth in cardiac muscle
11/15/2001US20010041679 Multiple site delivery of adenoviral vector for the induction of angiogenesis
11/15/2001US20010041673 A purine derivative or salt, useful for treating heart related diseases including congestive heart failure in mammals, particularly in human
1 ... 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 ... 3163